scholarly journals Shared Human Leukocyte Antigen (HLA) Coverage in dementia and Parkinson’s disease

2020 ◽  
Vol 5 (3) ◽  
pp. 45-54
Author(s):  
Lisa James ◽  
Apostolos Georgopoulos
2011 ◽  
Vol 17 (5) ◽  
pp. 376-378 ◽  
Author(s):  
Andreas Puschmann ◽  
Christophe Verbeeck ◽  
Michael G. Heckman ◽  
Alexandra I. Soto-Ortolaza ◽  
Timothy Lynch ◽  
...  

2021 ◽  
Vol 5 (2) ◽  
pp. 16-26
Author(s):  
Lisa M. James ◽  
Apostolos P. Georgopoulos

Human leukocyte antigen (HLA), which is critically involved in immune response to foreign antigens and in autoimmunity, has been implicated in dementia and Parkinson’s disease. Here we report on the correlations between the population frequencies of 127 HLA Class I and II alleles and the population prevalence of dementia and Parkinson’s disease in 14 Continental Western European countries, extending previous work1,2. We used these correlations to construct and compare HLA profiles for each disease3. We found that (a) the HLA profiles of the two diseases were significantly correlated across both HLA Class I and Class II alleles, (b) negative (“protective”) HLA-disease correlations did not differ significantly for either HLA class, but (c) positive (“susceptibility”) HLA-disease correlations were significantly higher in dementia than in Parkinson’s disease for both HLA classes of alleles. These findings indicate that (a) dementia and Parkinson’s disease share immunogenetic HLA-related mechanisms, (b) HLA-related protective mechanisms (presumably against pathogens) do not differ between the two diseases, but (c) HLA-related susceptibility mechanisms (presumably underlying autoimmunity) are significantly stronger in dementia than in Parkinson’s disease.


2021 ◽  
pp. 1-6
Author(s):  
Asuka Morizane ◽  
Jun Takahashi

Stem cell-based therapies for Parkinson’s disease are now being applied clinically. Notably, studies have shown that controlling the graft-induced immune response improves the results. In this mini-review, we concisely summarize current approaches used for this control. We focus on four modes of stem cell-based therapies: autologous transplantation, allogeneic transplantation with human leukocyte antigen-matching and allogeneic transplantation without, and finally the application of “universal” pluripotent stem cells. We also discuss immuno-suppressive treatments and the monitoring of immune reactions in the brain.


2016 ◽  
Vol 22 ◽  
pp. 6
Author(s):  
Leena Kinnunen ◽  
Valma Harjutsalo ◽  
Heljä-Marja Surcel ◽  
Christel Lamberg-Allardt ◽  
Jaakko Tuomilehto ◽  
...  

2008 ◽  
Vol 11 (1) ◽  
pp. E42-E45 ◽  
Author(s):  
Cheng-Hon Yap ◽  
Peter D. Skillington ◽  
George Matalanis ◽  
Bruce B. Davis ◽  
Brian D. Tait ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document